Myeloid-derived suppressor cells (MDSCs) accumulate in tumors and the peripheral blood of cancer patients and demonstrate cancer-promoting activity across multiple tumor types. A limited number of agents are known to impact MDSC activity. TLR8 is expressed in myeloid cells.
INTRODUCTION
Myeloid-derived suppressor cells (MDSCs) demonstrate a variety of functions that promote tumor growth as well as inhibit immune cell activity. Specific subtypes of MDSCs, monocytic MDSC (mMDSC) and granulocytic MDSC (gMDSC), can prevent the egress of activated CD8 T cells into the tumor, 1 downregulate TCR-zeta chain thus limiting T-cell activation, 2 and impede T-cell differentiation. 3 Elevated levels of MDSC indicate a poor prognosis or predict disease progression in many types of cancers. [4] [5] [6] High levels of MDSC in the peripheral blood of cancer patients prior to therapy is associated with a lack of or incomplete response to treatment for several cancers. 7, 8 Elevated blood MDSC has also been shown to be associated with a lack of clinical response to immune therapy in cancer patients [9] [10] [11] There are few agents known that impair MDSC function or survival, which could be used in the treatment of cancer.
Abbreviations: FL, fluorescence; gMDSC, granulocytic MDSC; Lin, Lineage; mDC, myeloid DC; MDSC, myeloid-derived suppressor cell; mMDSC, monocytic MDSC; pDC, plasmacytoid DC MDSCs modulate the adaptive immune response and can be activated via TLRs, including TLR2 and TLR4. [12] [13] [14] Signaling through TLR4, for example, causes MDSC to secrete IL-10 and promote a Th2 immune phenotype. 14 TLR signaling in MDSC is an important pathway resulting in control of inflammatory processes. 15 Motolimod is a small molecule selective TLR8 agonist and has been shown to stimulate type I cytokine production from antigenpresenting cells resulting in T-cell activation. 16 We questioned whether TLR8 was expressed in MDSCs and, if so, what effects TLR8 ligation would have on MDSC differentiation and function.
IRB-approved protocol. 18 Frozen PBMCs were thawed and washed before use. 19 
Cell subset isolation
PBMCs were stained with fluorochrome-conjugated monoclonal antibodies. Cell subtypes were isolated by BD FACS Aria II cell sorter.
Myeloid DCs (mDCs; Lineage (Lin)-HLA-DR+, CD11C+) and plasmacytoid DCs (pDCs; Lin-HLA-DR+, CD11c-, CD123+) and mMDSC (HLA-DR-CD14+) and gMDSC (Lin-HLA-DR-CD33+) were isolated. mMDSC, monocytes (HLA-DR+CD14+) and CD3+ T cells were also isolated.
TLR mRNA expression analysis
Total RNA was extracted from FACS-sorted mDC, pDC, mMDSC, and gMDSC. mRNA expression of TLR7, TLR8, and TLR9 was analyzed and normalized to b-actin/HPRT. 20 
Cell culture and treatment with TLR agonists
PBMCs (2 × 10 6 /ml) were cultured with 167 or 500 nM motolimod (VentiRx Pharmaceuticals, Seattle, WA, USA) or PBS for 24 h. In some assays, the cells were cultured with 0.5 M and 2 M of TLR7/8 agonist CL-075, 10 M and 50 M of TLR7 agonist Imiquimod, and 50 nM and 100 nM of TLR 9 agonist CpG ODN2006 with PBS control (all Invivogen, San Diego, CA). Doses were optimized as previously reported. 16 
Flow cytometry analysis
Cells were stained with antibodies and analyzed as percentage of mMDSC and gMDSC in PBMC. Cells were also stained with an annexin V PE, 7-AAD apoptosis detection kit (BD Biosciences, San Jose, CA).
All annexin V+ and 7-AAD+ cells were counted as dead. Cell surface death receptor FAS (CD95) was added and mean fluorescence (FL) of FAS expression was compared between control and treated mMDSC.
CD69+ and FAS-L+ cells percentage of CD3+CD4+ and CD3+CD8+
cells was compared between groups.
MACS and labeling of mMDSC
HLA-DR-CD14+ cells were enriched using microbeads (Miltenyl Biotec, Auburn, CA) and labeled with 3 M CFSE for 15 min at 37 • C using a Vybrant CFDA SE Cell Tracer Kit (Invitrogen, Carlsbad, CA). 21 Labeled mMDSCs were mixed with donor PBMC and cultured with PBS and 500 nM motolimod for 24 h. Both HLA-DR-and HLA-DR+CD14+ cells percentage of CFSE-labeled cells was analyzed.
FAS blocking
PBMCs were cultured with 2 g/ml of a FAS neutralizing antibody (clone ZB4; EMDMillipore, Billerica, MA) and isotype control for 1 h.
Cultured cells were incubated with or without 500 nM motolimod for 20 h before analysis. 
Cytokine analysis

Statistical analyses
GraphPad Prism version 6 was used (GraphPad Software, La Jolla, CA).
Paired t test compares the differences between control and treated cells. Differences in cytokine levels among groups were analyzed using a Mann-Whitney U test. P value < 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
mMDSCs, but not gMDSCs, express TLR8 mRNA
We have previously shown that TLR8 is expressed on monocytes and mDCs and the TLR8 agonist motolimod induces these cells to produce IL-12 and TNF-. 16 We questioned whether TLR8 was expressed on MDSC, a heterogeneic population of cells that contain at least two subsets, monocytic and granulocytic, both of which have variable immunosuppressive effects. 3 We found that TLR8 was highly expressed on the mMDSC subpopulation (HLA-DR-CD14+) but absent on gMDSC (Lin-HLA-DR-CD33+) (Fig. 1A) . Further, the levels of TLR8 expression were higher in mMDSC than in mDC. mMDSCs, as compared to gMDSCs, are uniquely capable of inhibiting T cells that have become activated. mMDSCs prevent CD44 expression on activated T cells and limit the movement of T cells from the blood to tissues. 23 mMDSCs also suppress expression of CD162 reducing T-cell adherence. 23 We evaluated the expression of TLR7 and TLR9 on MDSC in the same donors.
We found that TLR7 mRNA was not expressed on either mMDSC or gMDSC (Fig. 1B) . The expression of TLR9 on mMDSC and gMDSC was variable among donors (Fig. 1C ).
Motolimod treatment reduces the levels of mMDSC in PBMC
TLR8 is expressed on mDCs, which are some of the most effective antigen-presenting cells in the tumor microenvironment and capable of activating cancer-specific T cells. 24 Supplementary Fig. 1 . We next questioned whether we would observe similar effects in the PBMC of cancer patients. PBMCs derived from two patients with colon cancer, one with prostate cancer, and one with melanoma were similarly treated. The mMDSC percentage in PBMC was decreased in all patients treated with motolimod ( Fig. 2A) .
The reduction in mMDSC was specific for treatment with a TLR8 agonist
We examined the effects of a TLR7/8 agonist CL075, a TLR7 ago- Our results were unexpected as recent studies suggested incubation of mMDSC with a TLR7/TLR8 agonist could elicit significant IL-12 secretion and promote the differentiation of the cells into M1 macrophage over a 3-day period. 27 We did find that motolimod treatment could promote limited type I cytokine secretion in mMDSC (Supplementary Fig. 2A and B) but without any increase in HLA-DR+ cells (P > 0.05), which would indicate a shift in phenotype (P > 0.05; Supplementary Fig. 2C ). These varying effects may be due to distinct functional differences between TLR8 and TLR7 agonists. 28 TLR8 is present only in mDCs while TLR7 agonists will activate both mDCs and pDCs and B cells, which may result in differential stimulation of T cells. Moreover, studies demonstrate that type I cytokine levels produced by monocytes stimulated with a specific TLR8 agonist are 100 times greater than levels induced by a TLR7 agonist. 28 When PBMCs were treated with 500 nM motolimod, mMDSC death was further increased (84 ± 6%, vs. PBS, P = 0.0001; vs. 167 nM, P = 0.0455; Fig. 4A ). In contrast, cell death among total PBMC was no different from the control with both doses of motolimod (P > 0.05; Fig. 4B ; representative staining, Supplementary Fig. 3A and B). Motolimod treatment induced similar levels of cell death of the mMDSC in cancer patients (Fig. 2B) .
We have previously shown that motolimod does not directly activate T cells. 16 Treatment with the agent, however, indirectly activated T cells resulting in significant expression of CD69 on both CD4
(P = 0.0148) and CD8 (P = 0.0044) T cells compared to cells treated with PBS ( Supplementary Fig. 4A and B) . FASL was also significantly upregulated on CD4 and CD8 T cells with motolimod treatment (P = 0.0056 and 0.0257, respectively, as compared to PBS; Supplementary Fig. 4C and D) . Murine MDSCs express the death receptor FAS and induce apoptosis upon exposure to activated T cells. 30 We mea- 
Motolimod-dependent depletion of mMDSC partially restores T-cell activation
As shown in Fig. 5 , mMDSC significantly inhibited IL-2 secretion by CD3+ cells stimulated with CD3/CD28 antibody (mean ± SE of IL-2 (pg/ml): CD3/CD28 antibody alone, 3213 ± 1172 pg/ml; with mMDSC, 59 ± 13 pg/ml; P = 0.029). IL-2 secretion was partially restored when the cells were cocultured with motolimod (142 ± 36; P = 0.03).
Motolimod incubation did not directly stimulate IL-2 secretion from CD3+ cells or mMDSCs (Fig. 5 ).
CONCLUSIONS
Data presented here demonstrate that TLR8 is expressed in mMD- 
